摘要
CRISPR screening has been broadly used to discover new therapy targets,but these finding’successful clinical transition is still limited.In a recent study published in Nature,Jin et al.1 adopted CRISPR screening to dissect the resistance of hepatocellular carcinoma to lenvatinib,discovering the synergistic effect of EGFR inhibitor(gefitinib)and lenvatinib(multi-tyrosine kinase inhibitor,muti-TKI)combination therapy with encouraging clinical benefits.
基金
GW is supported by the Startup Fund of CAS Center for Excellence in Molecular Cell Science,the National Natural Science Foundation of China(32170917)
the Shanghai Pujiang Program(21PJ1413900)
YG is supported by the Construction Fund of Medical Key Disciplines of Hangzhou(2020–2024).
